| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $0 | 0 | 0 |
Sells | $952,742 | 13 | 100 |
| SUMER JACQUELYN L | Chief Legal Officer | 0 | $0 | 2 | $71,768 | $-71,768 |
| Jones Jeffrey Alan | Chief Medical Officer | 0 | $0 | 2 | $94,605 | $-94,605 |
| AHMED NADIM | President and CEO | 0 | $0 | 2 | $206,580 | $-206,580 |
| Michaelson Jennifer | Chief Scientific Officer | 0 | $0 | 7 | $579,788 | $-579,788 |
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Over the last 12 months, insiders at Cullinan Oncology, Inc. have bought $0 and sold $952,742 worth of Cullinan Oncology, Inc. stock.
On average, over the past 5 years, insiders at Cullinan Oncology, Inc. have bought $19.31M and sold $8.86M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 8,090 shares for transaction amount of $100,316 was made by AHMED NADIM (President and CEO) on 2022‑06‑06.
| 2025-02-25 | Sale | AHMED NADIM | President and CEO | 12,529 0.0203% | $8.53 | $106,872 | -4.91% | |
| 2025-02-25 | Sale | Jones Jeffrey Alan | Chief Medical Officer | 4,895 0.0079% | $8.53 | $41,754 | -4.91% | |
| 2025-02-25 | Sale | Michaelson Jennifer | Chief Scientific Officer | 3,756 0.0061% | $8.53 | $32,039 | -4.91% | |
| 2025-02-25 | Sale | SUMER JACQUELYN L | Chief Legal Officer | 3,756 0.0061% | $8.53 | $32,039 | -4.91% | |
| 2025-01-06 | Sale | Michaelson Jennifer | Chief Scientific Officer | 4,000 0.0072% | $12.51 | $50,040 | -27.16% | |
| 2024-12-24 | Sale | AHMED NADIM | President and CEO | 8,400 0.014% | $11.87 | $99,708 | -29.50% | |
| 2024-12-18 | Sale | Jones Jeffrey Alan | Chief Medical Officer | 4,632 0.0085% | $11.41 | $52,851 | -19.45% | |
| 2024-12-18 | Sale | Michaelson Jennifer | Chief Scientific Officer | 4,693 0.0087% | $11.41 | $53,547 | -19.45% | |
| 2024-12-18 | Sale | SUMER JACQUELYN L | Chief Legal Officer | 3,482 0.0064% | $11.41 | $39,730 | -19.45% | |
| 2024-12-12 | Sale | Michaelson Jennifer | Chief Scientific Officer | 3,489 0.0062% | $12.52 | $43,682 | -28.61% | |
| 2024-11-05 | Sale | Michaelson Jennifer | Chief Scientific Officer | 8,000 0.0134% | $15.64 | $125,120 | -43.77% | |
| 2024-09-05 | Sale | Michaelson Jennifer | Chief Scientific Officer | 8,000 0.0139% | $18.09 | $144,720 | -42.55% | |
| 2024-07-05 | Sale | Michaelson Jennifer | Chief Scientific Officer | 8,000 0.0137% | $16.33 | $130,640 | -26.64% | |
| 2024-05-07 | Sale | Michaelson Jennifer | Chief Scientific Officer | 5,606 0.0138% | $30.06 | $168,516 | -45.95% | |
| 2024-05-06 | Sale | Michaelson Jennifer | Chief Scientific Officer | 58,000 0.1331% | $28.07 | $1.63M | -44.03% | |
| 2024-02-01 | Sale | Savill Corrine | Chief Business Officer | 40,000 0.104% | $16.18 | $647,200 | -3.14% | |
| 2024-01-29 | Sale | Savill Corrine | Chief Business Officer | 40,000 0.0901% | $14.09 | $563,600 | +15.59% | |
| 2024-01-23 | Sale | Savill Corrine | Chief Business Officer | 21,316 0.0493% | $12.46 | $265,597 | +35.84% | |
| 2024-01-22 | Sale | Savill Corrine | Chief Business Officer | 18,684 0.0431% | $12.14 | $226,911 | +36.83% | |
| 2023-12-26 | Sale | AHMED NADIM | President and CEO | 4,272 0.0096% | $9.24 | $39,473 | +76.48% |
| AHMED NADIM | President and CEO | 430621 0.7297% | $3.51M | 1 | 7 | <0.0001% |
| Jones Jeffrey Alan | Chief Medical Officer | 174164 0.2951% | $1.42M | 0 | 8 | |
| Michaelson Jennifer | Chief Scientific Officer | 142004 0.2406% | $1.16M | 0 | 27 | |
| SUMER JACQUELYN L | Chief Legal Officer | 136895 0.232% | $1.12M | 0 | 8 | |
| UBS Oncology Impact Fund L.P. | 10 percent owner | 7648268 12.9599% | $62.41M | 1 | 18 | <0.0001% |
| LAMPERT MARK N | 4058854 6.8777% | $33.12M | 3 | 0 | +15.29% | |
| Jovan-Embiricos Morana | 1281952 2.1723% | $10.46M | 1 | 3 | <0.0001% | |
| Hughes Owen | President and CEO | 506226 0.8578% | $4.13M | 1 | 0 | <0.0001% |
| GADICKE ANSBERT | 244551 0.4144% | $2M | 1 | 18 | <0.0001% | |
| Savill Corrine | Chief Business Officer | 165990 0.2813% | $1.35M | 0 | 6 | |
| Trigilio Jeffrey | Chief Financial Officer | 83919 0.1422% | $684,779.04 | 1 | 12 | <0.0001% |
| Zawel Leigh | See Remarks | 37285 0.0632% | $304,245.60 | 0 | 7 | |
| Baeuerle Patrick | See Remarks | 0 0% | $0 | 0 | 2 |
$587,109,125 | 90 | 3.17% | $439.82M | |
$24,857,912 | 21 | -35.40% | $467.75M | |
$26,923,982 | 20 | -17.22% | $396.6M | |
$18,455,830 | 13 | 24.59% | $531.01M | |
$3,073,199 | 10 | 16.77% | $447.2M | |
$11,541,901 | 10 | 8.07% | $524.64M | |
$18,262,420 | 10 | 29.82% | $520.29M | |
$91,721,700 | 9 | -13.73% | $512.79M | |
Cullinan Oncology, Inc. (CGEM) | $38,624,786 | 9 | 1.26% | $481.56M |
$135,543,039 | 9 | -5.28% | $520.77M | |
$157,484,277 | 8 | 28.67% | $382.74M | |
$1,472,879 | 6 | -13.59% | $521.39M | |
$49,529,960 | 6 | 32.16% | $454.62M | |
$73,280,625 | 6 | -41.09% | $505.19M | |
$8 | 2 | 28.83% | $392.18M | |
$960,000 | 2 | 15.91% | $502.2M | |
$504,640 | 1 | 16.84% | $493.23M | |
$3,250,000 | 1 | -44.91% | $432.34M | |
$3,850,000 | 1 | -51.32% | $429.87M |
| Increased Positions | 72 | +40.68% | 7M | +10.84% |
| Decreased Positions | 74 | -41.81% | 6M | -9.82% |
| New Positions | 27 | New | 2M | New |
| Sold Out Positions | 24 | Sold Out | 4M | Sold Out |
| Total Postitions | 175 | -1.13% | 67M | +1.02% |
| Mpm Bioimpact Llc | $67,228.00 | 12.96% | 7.65M | 0 | 0% | 2024-12-31 |
| Bvf Inc/Il | $50,549.00 | 9.75% | 5.75M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $37,101.00 | 7.15% | 4.22M | -150,163 | -3.44% | 2025-03-31 |
| Deerfield Management Company, L.P. (Series C) | $29,705.00 | 5.73% | 3.38M | +99,399 | +3.03% | 2024-12-31 |
| Vanguard Group Inc | $25,809.00 | 4.98% | 2.94M | -62,487 | -2.08% | 2024-12-31 |
| Citadel Advisors Llc | $23,583.00 | 4.55% | 2.68M | +727,647 | +37.22% | 2024-12-31 |
| Blue Owl Capital Holdings Lp | $20,841.00 | 4.02% | 2.37M | +360,000 | +17.9% | 2024-12-31 |
| Franklin Resources Inc | $19,335.00 | 3.73% | 2.2M | +8,447 | +0.39% | 2024-12-31 |
| State Street Corp | $18,674.00 | 3.6% | 2.12M | -212,738 | -9.1% | 2024-12-31 |
| Alliancebernstein L.P. | $17,681.00 | 3.41% | 2.01M | +157,115 | +8.47% | 2024-12-31 |